Ludmila Danilova
Overview
Explore the profile of Ludmila Danilova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
9075
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alden S, Charmsaz S, Li H, Tsai H, Danilova L, Munjal K, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39832896
Background: Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To...
2.
Baretti M, Danilova L, Durham J, Betts C, Cope L, Sidiropoulos D, et al.
Nat Commun
. 2024 Nov;
15(1):9801.
PMID: 39532835
Pancreatic ductal adenocarcinoma (PDA) is characterized by low cytotoxic lymphocytes, abundant immune-suppressive cells, and resistance to immune checkpoint inhibitors (ICI). Preclinical PDA models showed the HDAC inhibitor entinostat reduced myeloid...
3.
Mendoza-Valderrey A, Dettmann E, Hanes D, Kessler D, Danilova L, Rau K, et al.
BJC Rep
. 2024 Nov;
2(1):38.
PMID: 39516255
Background: Brain metastases (BrMs) are a devastating complication of solid tumours. A better understanding of BrMs biology is needed to address their challenging clinical management. Methods: Immunogenomic and digital spatial...
4.
Lai J, Madan V, Qadri A, Danilova L, Yuan L, Jacobs V, et al.
Lab Invest
. 2024 Nov;
105(1):102178.
PMID: 39510251
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with a poor prognosis. One of the major mechanisms of immune evasion in MCC involves downregulation of major histocompatibility complex class...
5.
Palmer T, Kessler M, Shao X, Balan A, Yarchoan M, Zaidi N, et al.
Cancer Res Commun
. 2024 Oct;
4(12):3137-3150.
PMID: 39470352
SpliceMutr shows that splicing antigenicity changes in response to ICI therapies and that native modulation of the splicing machinery through mutations increases the contribution of splicing to the neoantigen load...
6.
Shu D, Ho W, Kagohara L, Girgis A, Shin S, Danilova L, et al.
Nat Immunol
. 2024 Oct;
25(11):2110-2123.
PMID: 39455893
Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances...
7.
Kao C, Charmsaz S, Alden S, Brancati M, Li H, Balaji A, et al.
J Clin Invest
. 2024 Oct;
134(20).
PMID: 39403935
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers of irAEs in a diverse pan-tumor...
8.
Sidiropoulos D, Shin S, Wetzel M, Girgis A, Bergman D, Danilova L, et al.
bioRxiv
. 2024 Oct;
PMID: 39386736
Graphical Abstract: Highlights: Integrated multi-modal spatial profiling of human PDAC tumors from neoadjuvant immunotherapy clinical trials reveal diverse spatial niches enriched in TLS.TLS maturity is influenced by tumor location and...
9.
Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5459-5472.
PMID: 39321200
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for...
10.
Guinn S, Kinny-Koster B, Tandurella J, Mitchell J, Sidiropoulos D, Loth M, et al.
Cancer Res
. 2024 Apr;
84(9):1517-1533.
PMID: 38587552
Significance: Adaptation of transfer learning to relate human single-cell RNA sequencing data to organoid-CAF cocultures facilitates discovery of human pancreatic cancer intercellular interactions and uncovers cross-talk between CAFs and tumor...